REGENERON PHARMACEUTICALS, INC.
REGNNasdaq · SIC 2834
$676.69
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +24.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$72.9B
Enterprise Value
$66.1B
P/E
16.5
P/S
4.9
P/B
2.3
EV/EBITDA
15.9
PEG
6.0
FCF Yield
—
Dividend Yield
0.5%
Revenue (TTM)
$14.9B
Net Income (TTM)
$4.4B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
24.3%
Net Margin
29.6%
ROE
14.1%
ROIC
12.6%
Debt / Equity
0.1
Net Cash
$6.8B
Return 1Y
+23.7%
Company profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.
- CEO
- Leonard S. Schleifer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 11,900
- Headquarters
- New York
- Website
- regeneron.com
Management & directors
- Pitofsky JasonSVP Controller
- Schleifer Leonard SBd. Co-Chair, President & CEO
- Yancopoulos GeorgeBd. Co-Chair, President & CSO
- Murphy Andrew JEVP Research
- Mccourt MarionEVP Commercial
- Van Plew Daniel PEVP & General Mgr, Industrial
- Fenimore Christopher R.EVP Finance CFO
- Larosa Joseph JEVP General Counsel and Secret
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-10-05
REGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.6B↑ +19.0%
Diluted EPS$6.75↓ -7.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| Net income | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| Diluted EPS | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Operating cash flow | $2.6B | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% |
| Net margin | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5B | $3.7B | $3.8B | $3.0B | $3.7B | $3.8B | $3.9B | $3.6B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.1B | $1.2B | $990.2M | $591.7M | $1.1B | $1.0B | $879.9M | $642.9M |
| Net income | $1.4B | $1.3B | $917.7M | $808.7M | $1.4B | $1.5B | $844.6M | $727.2M |
| Diluted EPS | $12.41 | $11.54 | $8.12 | $7.27 | $12.81 | $13.62 | $7.78 | $6.75 |
| Operating cash flow | $354.0M | $1.3B | $1.3B | $1.0B | $1.1B | $1.6B | $1.2B | $1.1B |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 30.2% | 31.7% | 26.1% | 19.5% | 29.4% | 27.3% | 22.7% | 17.8% |
| Net margin | 40.4% | 36.0% | 24.2% | 26.7% | 37.9% | 38.9% | 21.7% | 20.2% |
Company news
Jul 17, 2026
Jul 16, 2026
- 4d agoMerck Snags A First-Of-Its-Kind Approval, And Shares Jumpfinance.yahoo.com
- 4d agoMerck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pillfinance.yahoo.com
- 4d agoDow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumpsfinance.yahoo.com
- 4d agoCollect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upsidetrefis.com
- 4d agoMerck Gets Approval for Powerful Cholesterol-Cutting Pillfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | RYAN ARTHUR F | Sale | 200 | $650.15 | $130,030.00 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 24 | $703.46 | $16,883.04 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 15 | $704.28 | $10,564.20 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 14 | $705.56 | $9,877.84 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 7 | $706.74 | $4,947.18 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 6 | $709.45 | $4,256.70 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 5 | $711.49 | $3,557.45 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 4 | $707.40 | $2,829.60 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 2 | $714.13 | $1,428.26 | filing |
| 2026-05-01 | RYAN ARTHUR F | Sale | 1 | $712.09 | $712.09 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 40 | $779.71 | $31,188.40 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 14 | $775.58 | $10,858.12 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 13 | $776.62 | $10,096.06 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 9 | $777.42 | $6,996.78 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 8 | $774.58 | $6,196.64 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 4 | $778.24 | $3,112.96 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 3 | $772.76 | $2,318.28 | filing |
| 2026-04-01 | RYAN ARTHUR F | Sale | 1 | $771.32 | $771.32 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 20 | $789.28 | $15,785.60 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 11 | $785.48 | $8,640.28 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 10 | $783.62 | $7,836.20 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 9 | $784.48 | $7,060.32 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 7 | $786.61 | $5,506.27 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 5 | $779.69 | $3,898.45 | filing |
| 2026-03-02 | RYAN ARTHUR F | Sale | 3 | $780.69 | $2,342.07 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.